PRODERMIS is a next-generation aesthetics company advancing regenerative injectable science through clinically driven innovation. Its flagship platform, PROSCULPT™, is the world’s first dermal filler to combine cross-linked Hyaluronic Acid with Polynucleotides, engineered to deliver immediate structural support alongside long-term tissue quality improvement.

Designed to behave differently in tissue, PROSCULPT leverages the synergistic interaction between HA and PN to optimise injection control, natural integration, durability, and post-treatment comfort. This hybrid approach moves beyond traditional volumisation, supporting regenerative outcomes alongside aesthetic correction. Trusted by medical professionals worldwide, PRODERMIS continues to shape the future of regenerative aesthetics.